[Federal Register: January 2, 2002 (Volume 67, Number 1)]
[Page 83]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[[Page 83]]



Food and Drug Administration

Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


    This notice announces a forthcoming meeting of a public advisory 
committee of Food and Drug Administration (FDA). At least one portion 
of the meeting will be closed to the public.
    Name of Committee: Blood Products Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on January 16, 2002, from 
10 a.m. to 12:30 p.m.
    Location: Holiday Inn, Versailles Ballrooms I and II, 8120 
Wisconsin Ave., Bethesda, MD.
    Contact: William Freas, or Sheila D. Langford, Center for Biologics 
Evaluation and Research (CBER) (HFM-17), Food and Drug Administration, 
1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-0314, or FDA 
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in 
the Washington, DC area), code 19516. Please call the Information Line 
for up-to-date information on this meeting.
    Agenda: On January 16, 2002, the committee will hear presentations 
relevant to the site visit report on the review of the research 
programs of the Laboratory of Bacterial, Parasitic, and Unconventional 
Agents, and the Laboratory of Molecular Virology, Division of Emerging 
and Transfusion Transmitted Diseases, Office of Blood Research and 
Review, CBER.
    Procedure: On January 16, 2002, from 10:00 a.m. to 10:45 a.m., and 
from 11:30 a.m. to 12:30 p.m. the meeting is open to the public. 
Interested persons may present data, information, or views, orally or 
in writing, on issues pending before the committee. Written submissions 
may be made to the contact person by January 9, 2002. Oral 
presentations from the public will be scheduled between approximately 
11:30 a.m. to 12:30 p.m. on January 16, 2002. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before January 9, 2002, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Closed Committee Deliberations: On January 16, 2002, from 10:45 
a.m. to 11:30 a.m., the meeting will be closed to permit discussion 
where disclosure would constitute a clearly unwarranted invasion of 
personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss the 
reports of the review of individual research programs in the Division 
of Emerging and Transfusion Transmitted Diseases, Office of Blood 
Research and Review, Center for Biologics Evaluation and Research.
    FDA regrets that it was unable to publish this notice 15 days prior 
to the January 16, 2002, Blood Products Advisory Committee meeting. 
Because the agency believes there is some urgency to bring this issue 
to public discussion and qualified members of the Blood Products 
Advisory Committee were available at this time, the Commissioner of 
Food and Drugs concluded that it was in the public interest to hold 
this meeting even if there was not sufficient time for the customary 
15-day public notice.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: December 26, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 01-32253 Filed 12-27-01; 5:02 pm]